HOUSTON, April 26, 2018 /PRNewswire/ -- Clinical Trials Xpress (CTX), an initiative of the University of Texas System, has been named by PAREXEL, the world's leading innovator of biopharmaceutical services, as a member of its Global Site Alliance Network. Through the network, CTX will work with PAREXEL to further clinical development of novel drug therapies through the facilitation of research.
Designed to collaboratively combine and leverage expertise and resources to promote and expedite clinical trials and drug development processes, PAREXEL's Site Alliance Network includes strategically selected entities that are uniquely suited to enable faster clinical trial recruitment and patient enrollment, avoid trial delays and in turn allow for the rapid advancement and development of new cutting-edge medicine to reach patients.
"By becoming a PAREXEL Site Alliance member, CTX joins an elite group of healthcare organizations worldwide who are committed to the rapid advancement and development of new cutting-edge medicine to reach patients," added Dominic Clavell, PAREXEL's Vice President of Global Site Strategy. The PAREXEL alliance is expected to enhance the CTX platform of clinical trial opportunities across a broad range of therapeutic areas, including Oncology, Neurology and Psychiatry, and Infectious and Pulmonary Diseases.
CTX is changing the traditional landscape of how multi-site clinical trials are implemented at its academic and healthcare institutions. Envisioned by the Texas Regional CTSA Consortium (TRCC) leadership, the CTX Network was launched in 2015 in response to a national call for greater collaboration, efficiencies and streamlining of clinical trial processes. Recognized as "game-changing" by industry sponsors and clinical research organizations, the CTX operating model offers industry sponsors and physician investigators a single point of access and dedicated, experienced team who accelerate the launch of multi-site clinical trials for the benefit of all participating UT institutions. Using established master clinical trial agreements, IRB reciprocity or other accredited commercial IRB platforms, and centrally-negotiated study budgets common to all participating sites and their affiliates, the CTX model consolidates study start-up processes to open multi-site clinical trials in 100 calendar days or less.
"The PAREXEL strategic partnership aligns well with our vision of forging impactful research collaborations to bring greater exposure to all UT health institutions and improve overall patient care," said Raymond Greenberg, MD, PhD, Executive Vice Chancellor for Health Affairs at the UT System.
Centrally located in the Houston Medical Center, CTX is an innovative and unique academic model providing study start-up and other management services under a single umbrella to simplify processes and accelerate timelines. "The response from all stakeholders has been overwhelmingly positive," commented Patty Winger, President of Collaborative Clinical Research Solutions, Inc., whose company has been retained by UT System to establish the CTX infrastructure and whose staff manage the day-to-day network operations.
About Collaborative Clinical Research Solutions
Collaborative Clinical Research Solutions, Inc. (d/b/a CCRS Consultants) provides expert consultative services, strategic planning and dedicated staffing to develop and implement clinical research operating platforms tailored to specifically meet its client's needs. With decades of experience in site operations and network management, the CCRS portfolio is comprised of a broad range of academic enterprises, healthcare systems and other life sciences companies who share our vision for greater research collaboration and performance through operational efficiency and integrated systems. With a shared sense of purpose and urgency, CCRS Consultants, Inc. strives to implement research operating platforms that are Simplified, Scalable and Sustainable. For more information about CCRS Consultants, please visit www.ccrsconsultants.com
About Clinical Trials Xpress
Clinical Trials Xpress (CTX) is an initiative of the University of Texas System established to provide an efficient and scalable centralized operating model for conducting multisite clinical trials. Envisioned by the Texas Regional Clinical and Translational Science Award (CTSA) Consortium (TRCC), this collaboration brings together premier academic institutions, physician investigators and experienced research professionals under a shared vision to accelerate the pace of clinical trials from concept to completion. For more information about Clinical Trials Xpress, please visit: www.ClinicalTrialsXpress.org
About PAREXEL International
PAREXEL International Corporation is the world's leading innovator of biopharmaceutical services. We simplify our clients' journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world. For more information, visit www.PAREXEL.com.
PAREXEL is a trademark or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
About Texas Regional CTSA Consortium (TRCC)
The Texas Regional CTSA Consortium (TRCC) is a regional consortium of the national Clinical and Translational Science Award program. TRCC is a collaborative research network which advances innovative practices in translational science across Texas for the improvement of human health. The goal of the TRCC is to facilitate clinical and translational research and dissemination among the Texas CTSA hubs and other interested Texas and national biomedical research institutions. The Texas CTSA award institutions include UTHealth and UT MD Anderson in Houston, UT Southwestern Medical Center in Dallas, UT Health Science Center in San Antonio and UT Medical Branch in Galveston. For more information about the TRCC, please visit www.utsystem.edu/sites/trcc
Carla Kantara, PhD, MBA
Assoc. Vice President of Business Operations and Development
Collaborative Clinical Research Solutions, Inc. (d/b/a CCRS Consultants)
Supporting and Managing the UT System Clinical Trials Xpress
Phone: +1 713 500 7927
Email: [email protected]
SOURCE Collaborative Clinical Research Solutions, Inc.